Dose of inj piptaz for endophthalmitis
Reading File
Searching the Web
piperacillin tazobactam intravitreal dose endophthalmitis
Finding Sources
Finding Sources
Reading File
Reading Web Page
piperacillin tazobactam intravitreal dose endophthalmitis
Here is a complete summary of the dosing for injection piperacillin-tazobactam (pip-taz) in endophthalmitis:
Inj. Piperacillin-Tazobactam for Endophthalmitis
1. Intravitreal Injection (Primary Route for Endophthalmitis)
| Parameter | Details |
|---|---|
| Dose | 225-250 mcg in 0.1 mL |
| Route | Intravitreal injection |
| Frequency | Repeat every 48 hours as needed |
| Coverage | Gram-negatives (especially Pseudomonas aeruginosa), Staphylococcus epidermidis, MDR organisms, Mycobacterium abscessus |
- The dose of 250 mcg/0.1 mL was used in a landmark animal study (PMID 15721618) comparing pip-taz vs ceftazidime in P. aeruginosa endophthalmitis - both were equally effective.
- A published case report (PMC7574138) used 225 mcg/0.1 mL (repeated every 48 hours x 5 doses total) successfully in Mycobacterium abscessus endophthalmitis where all other agents were resistant.
- Note: one case used 250 mcg/0.01 mL (a different smaller volume; likely a typo in the source - the standard preparation is 0.1 mL).
2. Systemic IV (Adjunct in Severe/Exogenous Endophthalmitis)
| Indication | Dose |
|---|---|
| Standard adult dose | 4.5 g (4g pip + 0.5g taz) IV every 6-8 hours |
| P. aeruginosa / serious infections | 3.375 g IV every 6 hours or 4.5 g IV every 8 hours |
| Extended infusion (better PK/PD) | 3.375 g IV over 4 hours every 8 hours |
Adjust dose for renal insufficiency (GFR-based reduction).
Key Clinical Points
-
Pip-taz is NOT a first-line intravitreal antibiotic for routine endophthalmitis. The standard first-line intravitreal regimen remains vancomycin 1 mg/0.1 mL + ceftazidime 2.25 mg/0.1 mL (per Wills Eye Manual).
-
Pip-taz intravitreal is reserved as an alternative or adjunct when:
- Gram-negative (especially Pseudomonas) endophthalmitis is suspected/confirmed
- Organism is resistant to standard agents (e.g., MDR pathogens, Mycobacterium)
- Ceftazidime allergy or resistance
-
The intravitreal half-life data for pip-taz is not well established (shown as "NA" in published intravitreal antibiotic tables), so repeat dosing at 48 hours is guided by clinical response.
Sources:
- Wills Eye Manual, 8th Ed. (Appendix 12 - Intravitreal Antibiotics)
- Entokey - Intravitreal Antibiotics reference table
- PMC Case Report: M. abscessus endophthalmitis treated with intravitreal pip-taz 225 mcg/0.1 mL
- Experimental study (PMID 15721618): 250 mcg/0.1 mL effective in P. aeruginosa endophthalmitis
Inj Meropenem dose for endophthalmitis
Finding Sources
Searching the Web
meropenem intravitreal dose endophthalmitis mcg
Reading Web Page
meropenem intravitreal dose preparation endophthalmitis
Searching the Web
meropenem intravitreal injection endophthalmitis 100 mcg preparation protocol
Here is the complete dosing summary for meropenem in endophthalmitis:
Inj. Meropenem for Endophthalmitis
1. Intravitreal Injection
| Parameter | Details |
|---|---|
| Dose | 100 mcg in 0.1 mL |
| Vitreous half-life | ~2.6 hours (posterior route of clearance) |
| Repeat frequency | Not well established - based on clinical response |
| When to use | MDR gram-negatives, non-responding cases, Pseudomonas, ESBL producers |
Note: Meropenem is listed as an alternative/salvage agent for non-responding endophthalmitis, not a first-line drug. The Entokey intravitreal antibiotic reference table lists meropenem with a vitreous half-life of 2.6 h and posterior route of clearance, but notably the dose column is left blank in most published tables - indicating limited clinical standardization.
Important caveat: The intravitreal dose is not firmly standardized across guidelines. Some protocols list 100 mcg/0.1 mL based on extrapolation from experimental data. Always verify with your institutional pharmacy.
2. Systemic IV (Adjunct - for severe/exogenous endophthalmitis)
| Indication | Dose | Frequency |
|---|---|---|
| Standard serious infections | 1 g IV | Every 8 hours |
| Severe/MDR Pseudomonas, meningitis | 2 g IV | Every 8 hours |
| Infusion time | Over 15-30 min (or extended infusion over 3-4 hours for better PK/PD) | - |
| Renal adjustment | Required if CrCl <51 mL/min | - |
IV meropenem is particularly relevant in endophthalmitis because it achieves therapeutic vitreous concentrations when given systemically - making it a useful adjunct to intravitreal treatment in severe cases, to maintain antibiotic levels after intravitreal concentrations fall to subtherapeutic levels (PMC9954776).
Key Clinical Points
-
Meropenem intravitreally is a second-line / salvage agent used when:
- Standard regimen (vancomycin + ceftazidime) has failed
- MDR gram-negative organisms are confirmed/suspected
- Pseudomonas aeruginosa with ceftazidime resistance
- ESBL-producing organisms
-
The short intravitreal half-life of ~2.6 hours is a significant limitation - suggesting that systemic meropenem may actually be more practical to sustain vitreous drug levels than repeated intravitreal injections.
-
First-line intravitreal regimen remains: vancomycin 1 mg/0.1 mL + ceftazidime 2.25 mg/0.1 mL.
Sources:
- Entokey - Intravitreal Antibiotics table (vitreous PK data)
- Intravitreal Drugs in Endophthalmitis - Dr. Manish Bapayee protocol
- PMC9954776 - systemic meropenem achieving therapeutic vitreous concentrations
This is a shared conversation. Sign in to Orris to start your own chat.